PLA2G7 and early-onset autosomal dominant Alzheimer disease: Darapladib and rilapladib are potent reversible inhibitors of PLA2G7 that have previously been tested in large cohorts of patients for treatment of various pathologies including cardiovascular diseases, diabetic retinopathy, and Alzheimer's disease.13, 14, 15, 16